Infinite Epigenetics Acquires Tally Health to Build Full Aging Intervention Loop
The largest epigenetic testing merger yet aims to connect biological age scores directly to personalized interventions and supplements.
Summary
Infinite Epigenetics, parent company of TruDiagnostic, is acquiring Tally Health, the consumer longevity brand co-founded by Harvard geneticist David Sinclair. The deal is the biggest consolidation yet in the epigenetic age testing space. Rather than just measuring biological age, the combined company wants to close the loop: from cheek swab to personalized supplements and lifestyle interventions, all tracked over time. Tally retains its branding and CEO Melanie Goldey, while Infinite CEO Dr. Matthew Dawson leads the broader group. The goal is to use Infinite's large clinical datasets and scientific infrastructure to make Tally's consumer-facing insights more precise and evidence-backed, pushing epigenetics from a research novelty into a mainstream pillar of preventive healthcare.
Detailed Summary
The epigenetic age testing industry just made its biggest move yet. Infinite Epigenetics, the parent company behind clinical-grade testing platform TruDiagnostic, is acquiring Tally Health, the consumer longevity brand co-founded by Harvard geneticist Dr. David Sinclair. The deal signals a strategic shift from simply measuring biological age to actively intervening on it — and proving those interventions work.
At the heart of the acquisition is what Tally Health CEO Melanie Goldey calls solving the 'so what?' problem. Biological age scores have long fascinated health-conscious consumers, but critics have questioned whether those scores translate into meaningful clinical outcomes. By integrating Infinite's proprietary datasets and scientific infrastructure, the combined entity aims to make personalized recommendations more precise and grounded in stronger evidence.
Goldey reports that Tally's internal longitudinal data already shows customers improving both lifestyle behaviors and epigenetic age scores over time. The merger is designed to amplify that feedback loop: better data inputs, deeper personalization, more targeted supplement products, and a growing evidence base around what genuinely improves healthspan. Tally retains its branding and leadership, while Dr. Matthew Dawson helms the broader Infinite group.
The ambition is significant: Dawson wants epigenetic testing to become a standard, data-driven component of preventive healthcare rather than a niche research tool. By combining Tally's consumer reach with Infinite's clinical-grade engine, the company is betting it can finally force the science into something truly actionable at scale.
However, the deal also raises legitimate concerns. Creating a closed ecosystem — where the same company measures your aging and sells you the supplements to address it — blurs the line between medical insight and commercial incentive. The risk of 'science-washing,' where advanced research is diluted for marketing purposes, remains real. Independent validation of the intervention-to-outcome claims will be critical before this model can claim genuine clinical authority.
Key Findings
- Infinite Epigenetics acquires Tally Health in the largest epigenetic age testing consolidation to date.
- Combined entity aims to close the loop from biological age measurement to personalized supplement interventions.
- Tally's internal data shows customers improving both lifestyle behaviors and epigenetic age scores longitudinally.
- Merger grants access to larger clinical datasets, potentially improving personalization accuracy and evidence quality.
- Closed ecosystem model raises concerns about conflicts of interest between diagnostic insights and product sales.
Methodology
This is a news report and executive interview published by Longevity.Technology, a specialist longevity industry outlet. Evidence basis is primarily executive statements and internal company data rather than peer-reviewed research. No independent clinical trial data is cited to validate intervention outcomes.
Study Limitations
Key claims about customer improvements in epigenetic age rely on internal longitudinal data not yet published or peer-reviewed. The article is based on executive interviews, introducing potential promotional bias. Independent validation of the intervention-to-outcome feedback loop is needed before clinical conclusions can be drawn.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.